Den europeiske union - engelsk - EMA (European Medicines Agency)

novartis europharm ltd. - amlodipine, valsartan, hydrochlorothiazide - hypertension - angiotensin ii antagonists, plain, angiotensin ii antagonists, combinations - treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (hct), taken either as three single-component formulations or as a dual-component and a single-component formulation.

Den europeiske union - engelsk - EMA (European Medicines Agency)

novartis europharm limited  - onasemnogene abeparvovec - muscular atrophy, spinal - other drugs for disorders of the musculo-skeletal system - zolgensma is indicated for the treatment of:patients with 5q spinal muscular atrophy (sma) with a bi-allelic mutation in the smn1 gene and a clinical diagnosis of sma type 1, orpatients with 5q sma with a bi-allelic mutation in the smn1 gene and up to 3 copies of the smn2 gene.

Den europeiske union - engelsk - EMA (European Medicines Agency)

novartis europharm ltd - ofatumumab - leukemia, lymphocytic, chronic, b-cell - monoclonal antibodies - previously untreated chronic lymphocytic leukaemia (cll): arzerra in combination with chlorambucil or bendamustine is indicated for the treatment of patients with cll who have not received prior therapy and who are not eligible for fludarabine-based therapy. relapsed cll: arzerra is indicated in combination with fludarabine and cyclophosphamide for the treatment of adult patients with relapsed cll. refractory cll: arzerra is indicated for the treatment of cll in patients who are refractory to fludarabine and alemtuzumab.,

Den europeiske union - engelsk - EMA (European Medicines Agency)

novartis europharm limited - secukinumab - arthritis, psoriatic; psoriasis; spondylitis, ankylosing - immunosuppressants - plaque psoriasiscosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy.hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy.psoriatic arthritiscosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease modifying anti rheumatic drug (dmard) therapy has been inadequate.axial spondyloarthritis (axspa)ankylosing spondylitis (as, radiographic axial spondyloarthritis)cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.non-radiographic axial spondyloarthritis (nr-axspa)cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (nsaids).juvenile idiopathic arthritis (jia)enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.

Den europeiske union - engelsk - EMA (European Medicines Agency)

novartis europharm limited - indacaterol maleate - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - hirobriz breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease.

Den europeiske union - engelsk - EMA (European Medicines Agency)

novartis europharm limited - ranibizumab - wet macular degeneration; macular edema; diabetes complications; myopia, degenerative; choroidal neovascularization - ophthalmologicals - lucentis is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to choroidal neovascularisation (cnv)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)

Den europeiske union - engelsk - EMA (European Medicines Agency)

novartis europharm limited  - vildagliptin, metformin hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone.in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets.in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.

Den europeiske union - engelsk - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol maleate - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - oslif breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease.

Den europeiske union - engelsk - EMA (European Medicines Agency)

novartis europharm limited  - indacaterol maleate - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - onbrez breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease.

Den europeiske union - engelsk - EMA (European Medicines Agency)

novartis europharm limited  - brolucizumab - wet macular degeneration - ophthalmologicals - beovu is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (amd).